Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Eidos Therapeutics starts Phase III trial of AG10 in ATTR-CM

AG10 is designed to stabilise TTR and in turn prevent the molecular events leading to amyloidosis. Credit: Ed Uthman.



  • Eidos Therapeutics starts Phase III trial of AG10 in ATTR-CM

Go Top